A Study of Pumitamig and Chemotherapy Versus Nivolumab and Chemotherapy in People With Gastric, Gastroesophageal Junction (GEJ), or Esophageal Cancer

Full Title

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Yelena Janjigian’s office at 646-888-4286.

Protocol
26-129
Phase
Phase II/III (phases 2 and 3 combined)
Investigator
Yelena Y. Janjigian
Co-Investigators
Samuel Cytryn
Diseases
Upper Gastrointestinal › Esophageal Cancer
Upper Gastrointestinal › Gastric Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07221149
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description